Targeted. Novel. Best-In-Class.

At Ambit, we're combining our own KinomeScan technology with an innovative licensing strategy and a history of kinase expertise to discover, optimize and advance a sustainable pipeline of small molecule kinase inhibitors for the treatment of cancer and other diseases. Our lead compound AC220, a small molecule kinase inhibitor for the treatment of Acute Myeloid Leukemia, entered the clinic in 2006.

For more information about this and other product candidates in Ambit's pipeline, follow the links in the chart below.

For more information relating to Ambit's product pipeline and partnering opportunities, click here.

Back to top »